Bioceltix S.A.
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells … Read more
Bioceltix S.A. (BCX) - Net Assets
Latest net assets as of September 2025: zł27.00 Million PLN
Based on the latest financial reports, Bioceltix S.A. (BCX) has net assets worth zł27.00 Million PLN as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł30.17 Million) and total liabilities (zł3.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł27.00 Million |
| % of Total Assets | 89.51% |
| Annual Growth Rate | 70.33% |
| 5-Year Change | 1056.28% |
| 10-Year Change | N/A |
| Growth Volatility | 104.37 |
Bioceltix S.A. - Net Assets Trend (2018–2024)
This chart illustrates how Bioceltix S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bioceltix S.A. (2018–2024)
The table below shows the annual net assets of Bioceltix S.A. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł38.42 Million | +267.05% |
| 2023-12-31 | zł10.47 Million | +200.35% |
| 2022-12-31 | zł3.48 Million | -41.92% |
| 2021-12-31 | zł6.00 Million | +80.57% |
| 2020-12-31 | zł3.32 Million | +74.38% |
| 2019-12-31 | zł1.91 Million | +21.20% |
| 2018-12-31 | zł1.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bioceltix S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1358231200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł492.45K | 1.28% |
| Other Components | zł52.82 Million | 137.50% |
| Total Equity | zł38.42 Million | 100.00% |
Bioceltix S.A. Competitors by Market Cap
The table below lists competitors of Bioceltix S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xaar plc
PINK:XAARF
|
$71.32 Million |
|
YEAH1 Group Corp
VN:YEG
|
$71.34 Million |
|
Assertio Therapeutics Inc
NASDAQ:ASRT
|
$71.37 Million |
|
Frequency Therapeutics Inc
NASDAQ:KRRO
|
$71.41 Million |
|
Honghua Group Limited
F:4HB
|
$71.31 Million |
|
PetroShale Inc
OTCQB:PSHIF
|
$71.29 Million |
|
Bien Sparebank ASA
OL:BIEN
|
$71.28 Million |
|
Seoyon Co Ltd
KO:007860
|
$71.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioceltix S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,466,717 to 38,418,104, a change of 27,951,387 (267.1%).
- Net loss of 14,897,938 reduced equity.
- New share issuances of 42,849,325 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-14.90 Million | -38.78% |
| Share Issuances | zł42.85 Million | +111.53% |
| Total Change | zł- | 267.05% |
Book Value vs Market Value Analysis
This analysis compares Bioceltix S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.14x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 161.82x to 9.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | zł0.48 | zł77.40 | x |
| 2019-12-31 | zł0.58 | zł77.40 | x |
| 2020-12-31 | zł1.34 | zł77.40 | x |
| 2021-12-31 | zł1.90 | zł77.40 | x |
| 2022-12-31 | zł1.54 | zł77.40 | x |
| 2023-12-31 | zł2.67 | zł77.40 | x |
| 2024-12-31 | zł8.47 | zł77.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioceltix S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-38.78%) is above the historical average (-88.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -49.34% | -8429.21% | 0.00x | 2.10x | zł-932.90K |
| 2019 | -83.78% | -106422.47% | 0.00x | 1.69x | zł-1.79 Million |
| 2020 | -70.69% | -21747.72% | 0.00x | 1.45x | zł-2.68 Million |
| 2021 | -73.30% | 0.00% | 0.00x | 1.37x | zł-5.00 Million |
| 2022 | -173.20% | 0.00% | 0.00x | 1.16x | zł-9.44 Million |
| 2023 | -130.77% | 0.00% | 0.00x | 1.22x | zł-14.73 Million |
| 2024 | -38.78% | 0.00% | 0.00x | 1.09x | zł-18.74 Million |
Industry Comparison
This section compares Bioceltix S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $95,003,284
- Average return on equity (ROE) among peers: -44.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioceltix S.A. (BCX) | zł27.00 Million | -49.34% | 0.12x | $71.31 Million |
| Bioton S.A. (BIO) | $619.64 Million | 5.47% | 0.40x | $42.39 Million |
| Captor Therapeutics S.A. (CTX) | $124.20 Million | -26.23% | 0.16x | $69.93 Million |
| Mabion S.A. (MAB) | $-54.16 Million | 0.00% | 0.00x | $31.56 Million |
| Molecure S.A. (MOC) | $126.45 Million | -10.71% | 0.09x | $21.11 Million |
| Nanogroup SA (NNG) | $8.37 Million | -119.60% | 1.43x | $12.30 Million |
| Pharmena S.A. (PHR) | $8.98 Million | -45.66% | 0.29x | $2.62 Million |
| PolTREG S.A. (PTG) | $12.83 Million | -6.84% | 0.27x | $16.72 Million |
| Pure Biologics Spólka Akcyjna (PUR) | $7.21 Million | -65.22% | 2.02x | $2.90 Million |
| Ryvu Therapeutics SA (RVU) | $1.50 Million | -131.36% | 5.84x | $100.54 Million |